However, in MM, SGLT2 inhibitor use was associated with increased mortality in both those with (HR 2.62, 95% CI 1.10–6.24, p = 0.03) and without a diagnosis of congestive heart failure (HR 2.14, 95% CI 1.25–3.66, p = 0.006) (Supplementary Table S12). The gene discussed is SLC5A2; the disease is Miyoshi myopathy.